From the perspective of the development of the international pharmaceutical industry, China ranks first in terms of the level of China's pharmaceutical industry, in terms of pharmaceutical physical production and production of pharmaceuticals. In terms of medical value, China is in second place. Relevant experts said that compared with the United States, there is still a big gap in China. However, it is undeniable that with the improvement of the research and development level of domestic pharmaceutical companies, the prospects of China's pharmaceutical market will be immeasurable. In the near future, new domestic drug projects have made new progress.

(Pharmaceutical production source: China Pharmaceutical Network)

1.1 new drug anti-liver fibrosis innovative drug project signed

Shijiazhuang Four Medicine Co., Ltd. and Zhengzhou University signed a contract for the research and development project of 1.1 new drug anti-fibrosis innovative drug ADN-9. It is reported that "innovative drug ADN-9" is based on the natural product of andrographolide, through the molecular optimization of the system and screening of indications, the drug molecules that are particularly effective for the treatment of liver fibrosis.

The author has learned that the research and development team of Zhengzhou University's "Drug for the treatment of liver fibrosis innovative drugs ADN-9" led by Professor Dai Guizhen of Zhengzhou University has carried out systematic research on the project for more than ten years. The signing of this innovative drug program will bring good news to medical patients.

Anti-tuberculosis new drug donation project landed in Chengdu

Tuberculosis is a chronic and delayed infectious disease. China ranks third after India and Indonesia among the 30 countries with high burden of tuberculosis. In order to further explore the introduction of new anti-tuberculosis drugs and reasonable use experience, and promote the overall improvement of the level of diagnosis and treatment of tuberculosis in China, the Center for Tuberculosis Prevention and Control of China CDC led the organization of the donation of multidrug-resistant tuberculosis new drug bedaquinoline project. The Beida quinoline multidrug-resistant tuberculosis new drug donation project was implemented in the first six hospitals in China.

It is known that bentaquine is an antibiotic with a new mechanism of action, which can inhibit the Mycobacterium tuberculosis ATP (5'-adenosine triphosphate) synthetase, which is required for the energy production of Mycobacterium tuberculosis. Betaquinoline also provides an innovative treatment option for addressing the serious public health problem of MDR-TB.

In 2018, China’s first new class 1.1 drug was spent in Lianyungang.

The pharmaceutical strength of Lianyungang has increased rapidly in recent years. Recently, the first 1.1 new drugs in China have been spent in Lianyungang. The drug is a new research and development of the new drug, erlotinib hydrochloride, which was independently developed by Zhengda Tianqing Pharmaceutical Group. In 2015, the drug was granted the orphan drug for ovarian cancer by the US FDA.

According to Zhengda Tianqing, the drug is the first innovative small molecule drug based on international research and development processes and standards. It is also an anticancer drug that has been invested by the company so far. There was a reward for paying, and because of the excellent clinical performance, the anti-rostini was included in the priority review sequence by the Drug Evaluation Center, making it complete and approved for a short time.

Stem cell new drug and clinical research base project settled in Baoan

On May 10th, the “Stem Cell New Drug and Clinical Research Base” project with breakthrough key technologies in the industry officially settled in Baoan. It is understood that the project belongs to the stem cell treatment project. After decades of clinical experiments and research, it will eventually achieve industrialization. It has certain market development prospects, and also has advanced technology and is in line with the national biomedical industry policy.

Relevant experts believe that the current research on "new drug for mesenchymal stem cells" is at the international leading level. The settlement in Shenzhen is mainly for drug development, clinical trial research and industrial production of major diseases for stem cell treatment. Through the implementation of this project, a complete technology platform system for research and development of stem cell new drugs will be formed, and sales will be carried out at home and abroad to participate in the international competition for research and development of new stem cell drugs.

Patch For Diarrhea

Medical Cold Patch
Patch for diarrhea
[Name] Medical Cold Patch
[Package Dimension] 5cm 4pieces/box
The pain relief patch is composed of three layers, namely, backing lining, middle gel and protective film. It is free from pharmacological, immunological or metabolic ingredients.
[Scope of Application] For cold physiotherapy, closed soft tissue only.
[Indications]
The patches give a fast relief for diarrhea.
[How To Use a Patch]
Please follow the Schematic Diagram. One piece, one time.
The curing effect of each piece can last for 6-8 hours.
[Attention]
Do not apply the patch on the problematic skin, such as wounds, eczema, dermatitis,or in the eyes. People allergic to herbs and the pregnant are advised not to use the medication. If swelling or irritation occurs, please stop using and if any of these effects persist or worsen.notify your doctor or pharmacist promptly. Children using the patch must be supervised by adults.
[Storage Conditions]
Store below 30c in a dry place away from heat and direct sunlight.

Patch For Diarrhea,Medicated Patches For Arthiritis,Plaster For Diarrhea,Pad For Diarrhea

Shandong XiJieYiTong International Trade Co.,Ltd. , https://www.sdxjmedical.com